CARBOPLATIN INJECTION 10 MG
CARBOPLATIN : 10 MG · DIN 02125439 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is CARBOPLATIN INJECTION?
CARBOPLATIN INJECTION 10 MG contains CARBOPLATIN : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02125439, held by TEVA CANADA LIMITED, supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 08-Nov-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CARBOPLATIN INJECTION used for?
Treatment of advanced ovarian carcinoma of epithelial origin as first line or second line therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02125439 |
|---|---|
| Brand name | CARBOPLATIN INJECTION |
| Generic / active ingredient | CARBOPLATIN : 10 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 10 MG |
| Dosage form | LIQUID |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01XA02 CARBOPLATIN |
| AHFS class | 24:06.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 08-Nov-2013 |
| Original market date | 1995-12-31 00:00:00 |
How is it administered?
400 mg/m2 as a single I.V. dose by short-term (15-60 min) infusion. Repeat every 4 weeks if counts recover. Reduce dose for impaired renal function or risk factors.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15°C and 25°C. Protect from light. Diluted solutions stable for 8 hours at 15-30°C.
How is it supplied?
5 mL, 15 mL, 45 mL and 60 mL amber glass single use vials, one per carton.
Contraindications
Severe renal impairment; severe myelosuppression; bleeding tumors; history of severe allergic reactions to carboplatin, other platinum compounds, or mannitol.
Warnings and precautions
Potent drug; use only by experienced physicians. Dose-limiting hematologic toxicity (leukopenia, neutropenia, thrombocytopenia). Risk of anaphylaxis and neurotoxicity.
Is CARBOPLATIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by ACCORD HEALTHCARE INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01XA02 CARBOPLATIN. 3 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CARBOPLATIN INJECTION BP | 10 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02126680 |
| CARBOPLATIN INJECTION BP | 10 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02320371 |
| CARBOPLATIN INJECTION | 10 MG | SOLUTION | EUGIA PHARMA INC. | APPROVED | DIN 02535289 |
| CARBOPLATIN INJECTION | 10 MG | SOLUTION | OMEGA LABORATORIES LIMITED | DORMANT | DIN 02366053 |
| CARBOPLATIN INJECTION | 10 MG | SOLUTION | AURO PHARMA INC | APPROVED | DIN 02528916 |
| CARBOPLATIN INJECTION LIQ 10MG/ML | 10 MG | LIQUID | DAVID BULL LABORATORIES (PTY) LTD. | CANCELLED POST MARKET | DIN 01990438 |
| CARBOPLATIN INJECTION, BP | 10 MG | SOLUTION | STRIDES PHARMA CANADA INC | APPROVED | DIN 02420228 |
| PARAPLATIN INJ 150MG/VIAL | 150 MG | POWDER FOR SOLUTION | BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB | CANCELLED POST MARKET | DIN 00680060 |
| PARAPLATIN-AQ INJ 10MG/ML | 10 MG | LIQUID | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 00788759 |
Who else supplies CARBOPLATIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CARBOPLATIN appears in 38 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.